Abstract 5141
Background
SCLC is an aggressive disease with poor prognosis. Despite initial response to chemotherapy and radiotherapy, relapse occurs in most cases. To characterize genomic changes in SCLC over the course of therapy, we explored tracking tumor mutations in cell-free DNA (cfDNA) across post-treatment blood draws and comparing them to pre-treatment plasma and tissue profiles.
Methods
We retrospectively evaluated 235 samples collected from 24 subjects with late stage SCLC treated with first-line chemotherapy or chemoradiation in a prospective observational study. Tumor tissue samples were analyzed with the AVENIO Tumor Tissue Surveillance Kit (For Research Use Only, not for use in diagnostic procedures), a 198-kb next-generation sequencing panel covering 197 cancer genes. Matched peripheral blood mononuclear cells (PBMC), pre-treatment plasma, and multiple plasma from post-treatment timepoints were analyzed with the same panel using the AVENIO ctDNA Surveillance Kit (For Research Use Only, not for use in diagnostic procedures). A median input amount of 29 ng cfDNA, 129 ng tumor tissue DNA, and 50 ng PBMC DNA were sequenced to median deduplicated depths of 4491, 1315, and 6512, respectively. Somatic single nucleotide variants (SNVs) in tissue and plasma were identified by removing PBMC-matched germline or clonal hematopoietic mutations.
Results
We detected a median of 4 SNVs in tissue samples and a median of 100% (range 66 - 100%) of tissue SNVs in matched pre-treatment plasma. 96% (23/24) of subjects had at least one shared SNV between tissue and plasma, most commonly a TP53 mutation. A median of 7 SNVs were detected in pre-treatment plasma, whereas across all available post-treatment plasma (range 2 - 20 time points per subject), a median of 4 SNVs were detected. 53% of these mutations were not present in pre-treatment plasma or tissue.
Conclusions
Somatic mutations found in pre-treatment plasma were concordant with matched tissue, consistent with the highly metastatic nature of SCLC. ctDNA sequencing can provide additional molecular insights; in particular, detecting emergent mutations in ctDNA during treatment could advance our knowledge of SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Roche Sequencing Solutions, Inc.
Funding
Roche Sequencing Solutions, Inc.
Disclosure
S. Yaung: Full / Part-time employment: Roche. C. Woestmann: Full / Part-time employment: Roche. L. Xi: Full / Part-time employment: Roche. C. Ju: Full / Part-time employment: Roche. B. Hinzmann: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. M. Thomas: Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche. F. Lasitschka: Research grant / Funding (institution): Roche. M. Meister: Research grant / Funding (institution): Roche. M. Schneider: Research grant / Funding (institution): Roche. F.J.F. Herth: Honoraria (institution): Roche. T. Muley: Research grant / Funding (institution), Licensing / Royalties: Roche. B. Wehnl: Full / Part-time employment: Roche. J. Palma: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. X.M. Ma: Shareholder / Stockholder / Stock options, Licensing / Royalties, Full / Part-time employment: Roche.
Resources from the same session
1269 - One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan
Presenter: Shunji Takahashi
Session: Poster Display session 1
Resources:
Abstract
2868 - Prevalence of chemotherapy use and its impact on overall survival in patients with bone- and soft tissue sarcomas -A population-based analysis of 3746 patients
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract
3042 - Clinical course and therapeutic management of classical and endemic Kaposi’s Sarcoma (C/E KS)
Presenter: Lina Benajiba
Session: Poster Display session 1
Resources:
Abstract
3141 - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma
Presenter: Katarzyna Kozak
Session: Poster Display session 1
Resources:
Abstract
5449 - Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma
Presenter: Mrinal Gounder
Session: Poster Display session 1
Resources:
Abstract
4465 - SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial
Presenter: Antonia Digklia
Session: Poster Display session 1
Resources:
Abstract
5013 - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)
Presenter: Maud Pedrono
Session: Poster Display session 1
Resources:
Abstract
5614 - Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy.
Presenter: Paolo Tarantino
Session: Poster Display session 1
Resources:
Abstract
1033 - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe
Presenter: Vasilii Ostafiichuk
Session: Poster Display session 1
Resources:
Abstract
4094 - Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate
Presenter: Marília Silva
Session: Poster Display session 1
Resources:
Abstract